Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
17,000
Employees17,000
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
17,000
Employees17,000

GILD Key Statistics

Market cap
164.84B
Market cap164.84B
Price-Earnings ratio
18.55
Price-Earnings ratio18.55
Dividend yield
2.36%
Dividend yield2.36%
Average volume
6.03M
Average volume6.03M
High today
$134.73
High today$134.73
Low today
$132.57
Low today$132.57
Open price
$134.41
Open price$134.41
Volume
7.76M
Volume7.76M
52 Week high
$157.29
52 Week high$157.29
52 Week low
$108.46
52 Week low$108.46

Stock Snapshot

The current Gilead Sciences(GILD) stock price is $133.24, with a market capitalization of 164.84B. The stock trades at a price-to-earnings (P/E) ratio of 18.55 and offers a dividend yield of 2.36%.

On 2026-07-29, Gilead Sciences(GILD) stock moved within a range of $132.57 to $134.73. With shares now at $133.24, the stock is trading +0.5% above its intraday low and -1.1% below the session's peak.

Trading volume for Gilead Sciences(GILD) stock has reached 7.76M, versus its average volume of 6.03M.

Over the past 52 weeks, Gilead Sciences(GILD) stock has traded between a high of $157.29 and a low of $108.46.

Over the past 52 weeks, Gilead Sciences(GILD) stock has traded between a high of $157.29 and a low of $108.46.

GILD News

Simply Wall St 1d
Is Gilead Sciences Overvalued Following Its Trodelvy Europe Expansion Win?

Gilead Sciences (GILD) is in focus after the European Medicines Agency’s Committee for Medicinal Products for Human Use backed the use of Trodelvy plus Keytruda...

Is Gilead Sciences Overvalued Following Its Trodelvy Europe Expansion Win?
Simply Wall St 2d
AstraZeneca Pressure Puts Krystal Biotech, TG Therapeutics And Gilead Stocks In Focus

Healthcare investors are watching AstraZeneca closely after fresh comments about operating at Chinese speed, reaffirming a 2030 sales goal of $80b and reporting...

AstraZeneca Pressure Puts Krystal Biotech, TG Therapeutics And Gilead Stocks In Focus
Simply Wall St 3d
Gilead Wins Key Europe Backing For Trodelvy In Triple Negative Breast Cancer

The European Medicines Agency’s CHMP has issued a positive opinion for Trodelvy plus Keytruda in first line treatment of PD-L1 positive metastatic triple negati...

Gilead Wins Key Europe Backing For Trodelvy In Triple Negative Breast Cancer

Analyst ratings

79%

of 29 ratings
Buy
79.3%
Hold
20.7%
Sell
0%

More GILD News

Nasdaq 5d
Gilead Sciences Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $69.61, marking a -1.58% move from the previous day. This move lagged the S&P 500's daily gain o...

Gilead Sciences Stock Sinks As Market Gains: What You Should Know
TipRanks 6d
Gilead’s Trodelvy plus Merck’s Keytruda recommended by CHMP in breast cancer

Gilead (GILD) Sciences announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency, or EMA, has adopted a posit...

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.